AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMMURON LTD

0.067

0.000

Volume:- -

Turnover:- -

Market Cap:15.67M

PE:-2.08

High:0.067

Open:0.067

Low:0.067

Close:0.067

Loading ...

Overview Company News Filings

Immuron Ltd-Proposed Issue of Securities - Imc

THOMSON REUTERS

Immuron Sees Higher Fiscal 2025 Sales

MT Newswires Live

Immuron Limited Projects Record-Breaking Sales, On Track to Surpass A$7 Million This Financial Year

Immuron Ltd - on Track to Exceed a$7 Mln in Sales This Year

THOMSON REUTERS

Immuron Letter to Shareholders: Projects Update

THOMSON REUTERS

Immuron Ltd-Proposed Issue of Securities - Imc

THOMSON REUTERS

BRIEF-Immuron Travelan Highest Sales In History

Immuron Travelan® Highest Sales in History

THOMSON REUTERS

Immuron Travelan® highest sales in history

Immuron Posts Above AU$5 Million Revenue for Nine Months to March, Shares Up 12%

MT Newswires Live

BUZZ-Australia's Immuron gains on highest annual sales for its Travelan drug

Immuron Secures Exclusive Distribution Deal for Irritable Bowel Syndrome Product; Shares Down 3%

MT Newswires Live

BRIEF-Immuron Ltd Announces Exclusive Distribution Agreement For Australia And New Zealand

Immuron Ltd - Exclusive Distribution Agreement for Australia and New Zealand to Launch Proibs

THOMSON REUTERS

BRIEF-Immuron Travelan® continued strong sales growth

Immuron Travelan® Continued Strong Sales Growth

THOMSON REUTERS

Immuron's Global Sales for Travelan Surge 249% in December 2024 Quarter; Shares Rise 8%

MT Newswires Live

Immuron Partners With Monash University on Antimicrobial Resistance Research; Shares Down 12%

MT Newswires Live

BRIEF-Immuron Announces Travelan® Clinical Trial Update

Immuron Announces Travelan® Clinical Trial Update

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IMC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","market":"AU","secType":"STK","nameCN":"IMMURON LTD","latestPrice":0.067,"timestamp":1748931120000,"preClose":0.067,"halted":0,"volume":0,"delay":0,"nameEN":"IMMURON LTD","floatShares":200795594,"shares":233842333,"eps":-0.032226,"marketStatus":"Not Yet Opened","change":0,"latestTime":"06-03 16:12:00 AEST","open":0.067,"high":0.067,"low":0.067,"amount":0,"amplitude":0,"askPrice":0.075,"askSize":60021,"bidPrice":0.064,"bidSize":151937,"shortable":3,"etf":0,"ttmEps":-0.032226,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1748995200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.067,"openAndCloseTimeList":[[1748908800000,1748930400000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","floatShares":200795594,"roa":"-22.36%","roe":"-52.77%","lyrEps":-0.030443,"shares":233842333,"dividePrice":0,"high":0.067,"amplitude":0,"preClose":0.067,"low":0.067,"week52Low":0.054,"pbRate":"1.52","psRate":"2.40","week52High":0.11,"institutionHeld":0,"latestPrice":0.067,"committee":0.433652,"eps":-0.032226,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.032226,"open":0.067,"prevYearClose":0.079,"prevWeekClose":0.067,"prevMonthClose":0.067,"prevQuarterClose":0.067,"fiveDayClose":0.063,"twentyDayClose":0.067,"sixtyDayClose":0.078},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540742003","title":"Immuron Ltd-Proposed Issue of Securities - Imc","url":"https://stock-news.laohu8.com/highlight/detail?id=2540742003","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540742003?lang=en_us&edition=fundamental","pubTime":"2025-06-03 14:39","pubTimestamp":1748932770,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUE1VLS0V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2540755219","title":"Immuron Sees Higher Fiscal 2025 Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2540755219","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540755219?lang=en_us&edition=fundamental","pubTime":"2025-06-02 09:08","pubTimestamp":1748826496,"startTime":"0","endTime":"0","summary":"Immuron  said fiscal 2025 sales are \"on track\" to exceed AU$7 million, up from AU$4.9 million a year earlier, according to a May 30 filing with the Australian bourse.All of the US armed services participants in the field study for Travelan, the company's therapy candidate for traveler's diarrhea, have been deployed, the filing said.The biopharmaceutical firm expects the final visit of the last patient in July, with results slated for release in October, the filing added.The company also expects an investigational new drug submission for IMM-529, a drug candidate for colon infection, to the US Food and Drug Administration in August.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMC.AU"],"gpt_icon":0},{"id":"2539223305","title":"Immuron Limited Projects Record-Breaking Sales, On Track to Surpass A$7 Million This Financial Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2539223305","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539223305?lang=en_us&edition=fundamental","pubTime":"2025-05-30 18:00","pubTimestamp":1748599216,"startTime":"0","endTime":"0","summary":"Immuron Limited, an Australian-based biopharmaceutical company, has announced a positive financial outlook for the current year, projecting sales to exceed A$7 million. This marks a significant increase from the A$4.9 million achieved in the previous year. The company attributes this growth to record sales up to the end of March, continuing momentum through the Easter and ANZAC holiday periods, and the spring and summer break in North America. Immuron's Chief Executive Officer, Steven Lydeamore, highlighted that the company is on track to surpass these sales figures, underscoring a momentous rise in revenue. Additionally, Immuron's clinical product, IMM-124E , is anticipated to generate US$102 million in yearly revenue in the United States, based on Lumanity's opportunity assessment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for info","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL1y3bbG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU","NDAQ"],"gpt_icon":0},{"id":"2539995223","title":"Immuron Ltd - on Track to Exceed a$7 Mln in Sales This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2539995223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539995223?lang=en_us&edition=fundamental","pubTime":"2025-05-30 18:00","pubTimestamp":1748599200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUADPKPW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2539228020","title":"Immuron Letter to Shareholders: Projects Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2539228020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539228020?lang=en_us&edition=fundamental","pubTime":"2025-05-30 18:00","pubTimestamp":1748599200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUADPKPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2539235389","title":"Immuron Ltd-Proposed Issue of Securities - Imc","url":"https://stock-news.laohu8.com/highlight/detail?id=2539235389","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539235389?lang=en_us&edition=fundamental","pubTime":"2025-05-29 14:29","pubTimestamp":1748500162,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUE2WW6BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2526552825","title":"BRIEF-Immuron Travelan Highest Sales In History","url":"https://stock-news.laohu8.com/highlight/detail?id=2526552825","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526552825?lang=en_us&edition=fundamental","pubTime":"2025-04-11 06:23","pubTimestamp":1744323828,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Travelan Highest Sales In HistoryApril 10 (Reuters) - Immuron Ltd IMC.AX:IMMURON TRAVELAN® HIGHEST SALES IN HISTORYSource text: ID:nGNX5BJMtBFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA21C3HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU"],"gpt_icon":0},{"id":"2526540145","title":"Immuron Travelan® Highest Sales in History","url":"https://stock-news.laohu8.com/highlight/detail?id=2526540145","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526540145?lang=en_us&edition=fundamental","pubTime":"2025-04-11 06:00","pubTimestamp":1744322400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA21C3HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2526540089","title":"Immuron Travelan® highest sales in history","url":"https://stock-news.laohu8.com/highlight/detail?id=2526540089","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526540089?lang=en_us&edition=fundamental","pubTime":"2025-04-11 06:00","pubTimestamp":1744322400,"startTime":"0","endTime":"0","summary":"Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in history. March 2025 Quarter AUD$1.3 million up 2% on prior year. March 2025 Quarter AUD$0.8 million down 8% on prior year. March 2025 Quarter AUD$0.5 million up 28% on prior year. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a purified tablet preparation of hyper-immune bovine antibodies and other factors, which when taken wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immuron-travelan-highest-sales-history-220000438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Immuron Travelan® highest sales in history","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMRN","IMC.AU"],"gpt_icon":0},{"id":"2526088903","title":"Immuron Posts Above AU$5 Million Revenue for Nine Months to March, Shares Up 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526088903","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526088903?lang=en_us&edition=fundamental","pubTime":"2025-04-10 11:59","pubTimestamp":1744257542,"startTime":"0","endTime":"0","summary":"Immuron  reported AU$5.3 million sales revenue in the nine months ended March 31, the highest in its history, according to a Thursday Australian bourse filing.The company's March quarter sales were AU$1.3 million, up 2% from last year, of which AU$800,000 was from Australia and AU$500,000 from North America.The company reported an 86% increase in North American sales and a 34% increase in Australia sales, year to date, compared to 2024.The company's shares were up 12% in recent Thursday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMC.AU"],"gpt_icon":0},{"id":"2526837704","title":"BUZZ-Australia's Immuron gains on highest annual sales for its Travelan drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2526837704","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526837704?lang=en_us&edition=fundamental","pubTime":"2025-04-10 11:43","pubTimestamp":1744256624,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immuron gains on highest annual sales for its Travelan drug ** Shares of Immuron IMC.AX rise 11.7% to A$0.067** Stock set for its strongest session since January 14, if current trend holds** The biopharmaceutical co says it has exceeded full-year sales of A$5 million  for its Travelan drug, marking the co's highest annual sales ** About 437,320 shares change hands, 4.2x the 30-day average of 103,595 shares ** Stock down 15.2% YTD, including current session's moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nL3N3QO0D9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU"],"gpt_icon":0},{"id":"2517953396","title":"Immuron Secures Exclusive Distribution Deal for Irritable Bowel Syndrome Product; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517953396","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517953396?lang=en_us&edition=fundamental","pubTime":"2025-03-05 10:58","pubTimestamp":1741143496,"startTime":"0","endTime":"0","summary":"Immuron  entered into an exclusive distribution agreement to launch Calmino's ProlBS product in Australia and New Zealand, according to a Wednesday Australian bourse filing.Calmino developed ProIBS for the treatment of symptoms related to irritable bowel syndrome.The collaborative fee-free agreement includes all marketing and sales activities of ProlBS, the filing added.Company shares were down nearly 3% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7508","XJO.AU","XAO.AU","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2517107939","title":"BRIEF-Immuron Ltd Announces Exclusive Distribution Agreement For Australia And New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2517107939","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517107939?lang=en_us&edition=fundamental","pubTime":"2025-03-05 09:10","pubTimestamp":1741137041,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Ltd Announces Exclusive Distribution Agreement For Australia And New Zealand March 5 (Reuters) - Immuron Ltd IMC.AX:EXCLUSIVE DISTRIBUTION AGREEMENT FOR AUSTRALIA AND NEW ZEALAND TO LAUNCH PROIBSFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN0OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2517998720","title":"Immuron Ltd - Exclusive Distribution Agreement for Australia and New Zealand to Launch Proibs","url":"https://stock-news.laohu8.com/highlight/detail?id=2517998720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517998720?lang=en_us&edition=fundamental","pubTime":"2025-03-05 06:51","pubTimestamp":1741128672,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2504157142","title":"BRIEF-Immuron Travelan® continued strong sales growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2504157142","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504157142?lang=en_us&edition=fundamental","pubTime":"2025-01-17 20:53","pubTimestamp":1737118431,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Travelan® continued strong sales growthJan 17 (Reuters) - Immuron Ltd IMC.AX:IMMURON TRAVELAN® CONTINUED STRONG SALES GROWTHSource text: ID:nGNX5K2yv6Further company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250117:nTUA4WMTKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU"],"gpt_icon":0},{"id":"2504703158","title":"Immuron Travelan® Continued Strong Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2504703158","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504703158?lang=en_us&edition=fundamental","pubTime":"2025-01-17 19:00","pubTimestamp":1737111600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250117:nTUA4WMTKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2504068909","title":"Immuron's Global Sales for Travelan Surge 249% in December 2024 Quarter; Shares Rise 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504068909","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504068909?lang=en_us&edition=fundamental","pubTime":"2025-01-17 11:56","pubTimestamp":1737086192,"startTime":"0","endTime":"0","summary":"Immuron  reported global sales for its immune supplement, Travelan, of roughly AU$2.5 million in the December 2024 quarter, a surge of 249% year on year, according to a Friday filing with the Australian bourse.Sales in Australia soared 315% to nearly AU$1.9 million, while North American sales climbed 141% to AU$652,000.Global half-year sales jumped 70% to AU$4 million.The biopharmaceutical company's shares climbed past 8% in recent Friday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMC.AU"],"gpt_icon":0},{"id":"2503659098","title":"Immuron Partners With Monash University on Antimicrobial Resistance Research; Shares Down 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503659098","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503659098?lang=en_us&edition=fundamental","pubTime":"2025-01-15 11:11","pubTimestamp":1736910666,"startTime":"0","endTime":"0","summary":"Immuron  partnered with Monash University to develop new therapeutic drug candidates targeting antimicrobial-resistant pathogens, according to a Wednesday filing with the Australian bourse.The collaboration will involve the Biomedicine Discovery Institute research team and make use of the Immuron technology platform, the filing said.The parties will negotiate whether to jointly develop or commercialize the outcomes of the research collaboration on commercially reasonable terms after the results are known, per the filing.Shares fell past 12% in afternoon trade Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2503152691","title":"BRIEF-Immuron Announces Travelan® Clinical Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2503152691","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503152691?lang=en_us&edition=fundamental","pubTime":"2025-01-14 19:38","pubTimestamp":1736854698,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Announces Travelan® Clinical Trial UpdateJan 14 (Reuters) - Immuron Ltd IMC.AX:IMMURON ANNOUNCES TRAVELAN® CLINICAL TRIAL UPDATESource text: ID:nGNX62sh4YFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUA1RTLMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2503528049","title":"Immuron Announces Travelan® Clinical Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2503528049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503528049?lang=en_us&edition=fundamental","pubTime":"2025-01-14 19:00","pubTimestamp":1736852400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUA1RTLMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-02-28","symbol":"IMC.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1677502800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMC.AU\",market:\"AU\",,,undefined,":[]}}